KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Interest Expenses (2016 - 2023)

Supernus Pharmaceuticals has reported Interest Expenses over the past 13 years, most recently at $910000.0 for Q2 2023.

  • Quarterly Interest Expenses fell 49.72% to $910000.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $910000.0 through Mar 2024, down 86.28% year-over-year, with the annual reading at $2.4 million for FY2023, 65.84% down from the prior year.
  • Interest Expenses was $910000.0 for Q2 2023 at Supernus Pharmaceuticals, down from $1.5 million in the prior quarter.
  • Over five years, Interest Expenses peaked at $6.1 million in Q1 2021 and troughed at $910000.0 in Q2 2023.
  • The 5-year median for Interest Expenses is $5.7 million (2019), against an average of $4.4 million.
  • Year-over-year, Interest Expenses surged 718.69% in 2019 and then plummeted 73.14% in 2022.
  • A 5-year view of Interest Expenses shows it stood at $5.8 million in 2019, then grew by 5.52% to $6.1 million in 2020, then decreased by 2.66% to $5.9 million in 2021, then crashed by 73.14% to $1.6 million in 2022, then crashed by 42.91% to $910000.0 in 2023.
  • Per Business Quant, the three most recent readings for SUPN's Interest Expenses are $910000.0 (Q2 2023), $1.5 million (Q1 2023), and $1.6 million (Q4 2022).